LogicBio Therapeutics Inc (NASDAQ:LOGC) – Research analysts at William Blair issued their Q1 2020 EPS estimates for shares of LogicBio Therapeutics in a note issued to investors on Tuesday, May 14th. William Blair analyst R. Prasad anticipates that the company will earn ($0.50) per share for the quarter. William Blair also issued estimates for LogicBio Therapeutics’ Q2 2020 earnings at ($0.73) EPS, Q3 2020 earnings at ($0.67) EPS and Q4 2020 earnings at ($0.53) EPS.
LOGC has been the topic of a number of other reports. Zacks Investment Research downgraded LogicBio Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 16th. Roth Capital started coverage on LogicBio Therapeutics in a research report on Wednesday, May 1st. They set a “buy” rating and a $26.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. LogicBio Therapeutics has an average rating of “Buy” and an average price target of $24.00.
LogicBio Therapeutics (NASDAQ:LOGC) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.02).
A number of institutional investors and hedge funds have recently bought and sold shares of LOGC. Victory Capital Management Inc. purchased a new stake in shares of LogicBio Therapeutics in the fourth quarter valued at $31,000. American International Group Inc. purchased a new stake in shares of LogicBio Therapeutics in the fourth quarter valued at $56,000. New York State Common Retirement Fund purchased a new stake in shares of LogicBio Therapeutics in the first quarter valued at $57,000. Deutsche Bank AG purchased a new stake in shares of LogicBio Therapeutics in the fourth quarter valued at $115,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of LogicBio Therapeutics by 26.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 20,515 shares of the company’s stock valued at $203,000 after acquiring an additional 4,315 shares in the last quarter. Institutional investors own 54.48% of the company’s stock.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Further Reading: Debt-To-Equity Ratio
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.